Brief: Genfleet Therapeutics (Shanghai) Says GFH375 Granted Breakthrough Therapy Designation By China's NMPA
09/04/2026 02:19
April 9 (Reuters) - GenFleet Therapeutics (Shanghai) Inc 2595.HK: GFH375 GRANTED BREAKTHROUGH THERAPY DESIGNATION BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION Further company coverage: 2595.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GenFleet Therapeutics (Shanghai)
See all newsHK-listed GenFleet jumps on positive progress of cancer drug
GenFleet hits over 3-week high as cancer drug makes progress on BTD list
Brief: GenFleet Therapeutics (Shanghai) Says GFH375 Combined With Cetuximab Placed On Proposed BTD List
HK-listed GenFleet rises most in a month on repurchasing shares
Brief: GenFleet Therapeutics (Shanghai) Reports Loss Of RMB220.17 Million For Six Months